Agenus Enters into Non-Exclusive License Agreement with VaxLogic for QS-21 Stimulon1 Adjuvant

Agenus Inc.

today announced that it is has entered into a non-exclusive license agreement with VaxLogic, LLC, a subsidiary of PharmLogic LLC, for the use of QS-21 Stimulon®1 adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates. This agreement enables VaxLogic to immediately utilize the QS-21 Stimulon adjuvant in development for a nicotine addiction vaccine, and contemplates expansion into the following additional vaccine indications: poison ivy, peanut allergy, insect allergy, shellfish allergy, allergic rhinitis, and allergic asthma. VaxLogic will develop these vaccine candidates using Agenus' QS-21 Stimulon adjuvant and select defined antigens, with the objective of enhancing the immune response and boosting vaccine